welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Coxib-inhibition of Duodenal Polyp Growth in FAP
study id #: NCT00844727
condition: Duodenal Polyposis
Preliminary data indicate a protective effect on the development of duodenal polyps by coxib treatment. The hypothesis of the present study is that normal therapy doses of rofecoxib for 1 year would stop or reverse the development of premalignant adenomatous lesions in the duodenal mucosa of FAP patients.
start date: September 2003
estimated completion: April 2004
last updated: July 6, 2011
phase of development: Phase 2, Phase 3
size / enrollment: 38
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- FAP patient with previous colectomy and confirmed polyposis
- NSAID hypersensitivity
expertly curated content related to this topic
Genotype and Phenotype of Patients with Both Familial Adenomatous Polyposis and Thyroid CarcinomaThe incidence of thyroid carcinoma in fa...
BCIR – Olympia Medical Center Los Angeleshttps://www.youtube.com/channel/UCEdZLy_...
Familial Investigations of Childhood Cancer PredispositionWhile it is well recognized that heredit...
Identification of 5 Novel Germline APC Mutations and Characterization of Clinical Phenotypes in Japanese Patients wi...BACKGROUND : Familial adenomatous polypo...
F.A.P.ology101: Mapping out Surgery Routeshttps://www.youtube.com/watch?v=k8sOJS5J...
Andalusian Registry for Familial Adenomatous Polyposis. Analysis of Patients IncludedOBJECTIVE : To evaluate the phenotype an...
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)A study to evaluate rofecoxib in the tre...